Skip to main content

Table 2 Phospho-RTK profiling results for canine primary urothelial carcinoma tumor samples and urothelial carcinoma cell lines

From: Characterization of receptor tyrosine kinase activation and biological activity of toceranib phosphate in canine urothelial carcinoma cell lines

Receptor tyrosine kinase

Urothelial carcinoma tumors n (%)

Urothelial carcinoma cell lines n (%)

PDGFRa

1 (11%)

1 (25%)

PDGFRb

3 (33%)

1 (25%)

KIT

3 (33%)

1 (25%)

Flt-3

2 (22%)

0 (0%)

M-CSF R

3 (33%)

1 (25%)

VEGFR1

2 (22%)

0 (0%)

VEGFR2

3 (33%)

0 (0%)

VEGFR3

5 (56%)

0 (0%)

EGFR

9 (100%)

4 (100%)

ErbB2

8 (89%)

4 (100%)

ErbB3

3 (33%)

2 (50%)

ErbB4

4 (44%)

1 (25%)

FGFR1

4 (44%)

1 (25%)

FGFR2

4 (44%)

1 (25%)

FGFR3

4 (44%)

1 (25%)

FGFR4

2 (22%)

0 (0%)

Insulin R

7 (78%)

2 (50%)

c-RET

3 (33%)

1 (25%)

ROR1

8 (89%)

4 (100%)

ROR2

8 (89%)

3 (75%)

Tie-1

9 (100%)

4 (100%)

Tie-2

7 (78%)

3 (75%)

  1. The 22 most commonly observed phosphorylated receptor tyrosine kinases on the phospho-RTK Arrays are listed in the first column. The number of primary urothelial carcinoma tumors with the respective phosphorylated RTK is shown as a total and percentage of all tumors (n = 9). The number of primary urothelial carcinoma cell lines with the respective phosphorylated RTK is shown in the right column as a total and percentage of all cell lines (n = 5)